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Leishmaniasis is an increasing public health problem and eﬀective vaccines are not currently available. We have previously
demonstrated that vaccination with ribosomal proteins extracts administered in combination of CpG oligodeoxynucleotides
protects susceptible BALB/c mice against primary Leishmania major infection. Here, we evaluate the long-term immunity to
secondary infection conferred by this vaccine. We show that vaccinated and infected BALB/c mice were able to control a secondary
Leishmania major challenge, since no inﬂammation and very low number of parasites were observed in the site of reinfection.
In addition, although an increment in the parasite burden was observed in the draining lymph nodes of the primary site of
infection we did not detected inﬂammatory lesions at that site. Resistance against reinfection correlated to a predominant Th1
response against parasite antigens. Thus, cell cultures established from spleens and the draining lymph node of the secondary site
of infection produced high levels of parasite speciﬁc IFN-γ in the absence of IL-4 and IL-10 cytokine production. In addition,
reinfected mice showed a high IgG2a/IgG1 ratio for anti-Leishmania antibodies. Our results suggest that ribosomal vaccine, which
prevents pathology in a primary challenge, in combination with parasite persistence might be eﬀective for long term maintenance
of immunity.
1.Introduction
Protozoa of the genus Leishmania are obligate intracellular
parasites of the mononuclear phagocytic lineage. Leishma-
nia infection causes a group of diseases ranging from self-
healing cutaneous ulcers to potentially lethal fatal visceral
infection, globally known as leishmaniasis [1]. L. major is
the main causative agent of cutaneous leishmaniasis (CL)
in the Old World. In humans, CL due to L. major infection
is self-limiting and healing is associated with resistance to
reinfection.Thisacquiredimmunitytoreinfectioninnatural
Leishmania hosts suggeststhata vaccineis feasible.However,
there are no available vaccines against human leishmaniasis
[2].
Eﬀective primary immunity against L. major in mouse
requires an IL-12 dependent production of IFN-γ from
CD4+T cells (Th1 response) and CD8+ T cells that mediates
a nitric oxide-dependent killing by infected macrophages [3,
4]. In contrast, susceptibility correlates with the dominance
of an IL-4 driven Th2 response, as it has been observed
in certain mice strains like BALB/c [3, 4]. Subcutaneous
(s.c.) experimental infection of BALB/c mice with a high2 Journal of Biomedicine and Biotechnology
dose inoculum of stationary phase promastigotes induces
rapidly evolving lesions that correlated with the generation
of strong Th2 responses [5]. This model of experimental CL
has been extensively used to explore the protective role of
several parasite antigens combined with diﬀerent adjuvants
[2, 6, 7]. The immunization with certain parasite proteins,
irrespective of their cellular location (surface or intracel-
lular parasite antigens), inoculated with Th1 modulating
adjuvants can induce immune responses that resulted in
protection [8, 9]. The production of parasite speciﬁc IFN-
γ combined with the control of the production of the disease
associated IL-4 and IL-10 cytokines has been correlated to
protection against the development of CL in vaccinated
BALB/c mice [10]. Protective cell mediated immunity can
also be induced in BALB/c mice after s.c. infection using a
nonpathogenic challenge of L. major promastigotes (leish-
manization) [11–14]. Leishmanized mice developed very
low or no pathology after primary infection and acquired
resistance against a pathogenic rechallenge [11, 13, 14].
LeishmanizationinducedparasitespeciﬁcTh1responsesthat
were able to control the secondary challenge made in a
distant site [13, 14].
In a previous work, we have shown that during L.
major infection, susceptible BALB/c mice develop a Th2
response against parasite ribosomal crude extracts puriﬁed
from promastigotes [15]. Vaccination with the parasite ribo-
somal proteins (LRP) combined with CpG oligodeoxynu-
cleotides (CpG ODN) as adjuvant induced a speciﬁc Th1
response,sincevaccinatedmicedevelopedanti-LRPantibod-
ies of the IgG2a isotype and their splenocytes produced high
amounts of IFN-γ, but not IL-4, after in vitro stimulation
with LRP [15]. The immune state induced by vaccination
conferred protection against a primary challenge with L.
major parasites in the footpad. After infection, a Leishma-
nia speciﬁc IL-12 dependent production of IFN-γ and a
r e d u c e dp r o d u c t i o no fI L - 4a n dI L - 1 0w e r ea s s o c i a t e dt o
protection [15].
In this work, we have analyzed whether or not vaccinated
and protected mice were able to control the development of
CL after a secondary challenge. To this end, mice vaccinated
with LRP + CpG ODN were infected in the footpad with a
pathogenic challenge of L. major parasites. The development
of footpad swelling was analyzed over a period of 18 weeks
as a stringent test of vaccine induced protection. Since no
CL pathology was found during the follow up, mice were
reinfected into the ear dermis with a low dose pathogenic
challenge of L. major metacyclic promastigotes. Our results
showed that vaccinated and infected mice developed a resis-
tant phenotype to parasite associated disease at a secondary
site of infection.
2.MaterialsandMethods
2.1. Animals and Parasites. Female BALB/c mice (4–6 week-
old) were purchased from Harlan Interfauna Ib´ erica S.A.
(Barcelona, Spain). L. major parasites (WHOM/IR/-/173)
and clone V1 (MHOM/IL/80(Friedlin)) were kept in a vir-
ulent state by passage in BALB/c mice. L. major amastigotes
were obtained and transformed to promastigote by cultur-
ing at 26◦C in Schneider’s medium (Gibco, BRL, Grand
Island, NY, USA) supplemented with 20% foetal calf serum.
Metacyclic promastigotes of L. major (clone V1) were
isolated from stationary cultures by negative selection as
described in [16] using peanut agglutinin (Vector Laborato-
ries, Burlingame, CA, USA).
2.2.ParasiteAntigens,AdjuvantandImmunizations . Soluble
Leishmania major antigen (SLA) was prepared as described
[17]. Brieﬂy, L. major promastigotes were harvested from
culture and washed four times in phosphate-buﬀered saline
(PBS). The parasites were suspended in PBS and subjected
to three freezing and thawing cycles and sonicated with
ﬁve cycles of 30 seconds at 38MHz. After cell lysis, sol-
uble antigens were separated from the insoluble fraction
by centrifugation for 15 minutes at 12,000 × g using a
microcentrifuge. L. major ribosomal proteins (LRP) were
preparedasdescribed[15].Phosphorothioate-modiﬁedCpG
ODN (5 -TCAACGTTGA-3  and 5 - GCTAGCGTTAGCGT-
3 ) were synthesized by Isogen (The Netherlands).
Six mice were s.c. immunized in the right footpad with
12μgo fL. major LRP combined with 25μg of each CpG
ODN in a volume of 30μl. Control groups (n = 6) received
either CpG ODN or phosphate saline buﬀer PBS. Mice were
immunized three times at two-week intervals.
2.3. Parasite Challenge. The primary parasite challenge was
done by s.c. inoculation in the left footpad with 5 × 104
stationary-phase promastigotes of L. major (WHOM/IR/-
/173) in a volume of 30μl, four weeks after the last vaccine
inoculation. The secondary infection was done at week 18
after primary infection with 1000 metacyclic promastigote
of L. major (clone V1) isolated from stationary cultures by
negative selection using peanut agglutinin (Vector Laborato-
ries, Burlingame, CA). Metacyclic forms were injected into
the dermis (i.d.) of both ears of each mouse in a volume of
10μl.
Footpad swelling was measured with a metric calliper
and calculated as thickness of the left footpad minus
thickness of the right footpad. Evolution of the ear lesion
was monitored by measuring the diameter of the indurations
with a metric calliper.
2.4. Estimation of Parasitic Load. The number of parasites
was determined by limiting dilution assay [18]. Brieﬂy, ears
wererecoveredfrominfectedmiceandtheventralanddorsal
sheets were separated. Ear sheets were deposited in RPMI
medium containing Liberase CI enzyme blend (50μgml −1)
(Roche, Mannheim, Germany). After an incubation period
of 2 hours at 37◦C, the tissues were cut into small pieces,
homogenized and ﬁltered using a cell strainer (70μm-pore
size). The homogenized tissue was serially diluted in a 96-
well ﬂat-bottomed microtiter plate containing Schneider’s
medium plus 20% FCS. The number of viable parasites was
determinedfromthehighestdilutionatwhichpromastigotes
could be grown up to 7-day incubation at 26◦C. The
numberofparasiteswasalsodeterminedinthelocaldrainingJournal of Biomedicine and Biotechnology 3
lymph nodes (DLN) of infected ears (retromaxillar) and
footpad(popliteal)andinthespleen.Organswererecovered,
mechanicallydissociated,homogenizedandﬁlteredandthen
serially diluted as above. Parasite load is expressed as the
number of parasites in the whole organ.
2.5. Measurement of Cytokines in Supernatants. Splenocytes
and DLN cells suspensions were seeded in complete RPMI
medium (RPMI 1640 supplemented with 10% FCS, 2mM
glutamine, and 10mM 2-mercaptoethanol). 3 × 106 cells
were seeded in 48-well plates during 48-hour at 37◦Ci n
the presence of LRP (12μgml −1)o rS L A( 1 2μgml −1). The
release of IFN-γ, IL-10, and IL-4 was measured in the
supernatants of splenocytes and DLN cell cultures using
commercial ELISA kits (Diaclone, Besanc ¸on,France).
2.6. Analysis of the Humoral Responses. Reciprocal end-point
titre (deﬁned as the inverse of the highest serum dilution
factor giving an absorbance >0.2) against LRP and SLA was
determined by serial dilution of the sera assayed by ELISA
usinganti-IgG1(1/1000)andanti-IgG2a(1/500)horseradish
peroxidase-conjugated anti-mouse immunoglobulins as sec-
ondary antibodies (Nordic Immunological Laboratories,
Tilburg, The Netherlands). Plates were coated with 100μlo f
LRP (5μgml −1 in PBS) or SLA (2μgml −1 in PBS).
2.7. Statistical Analysis. Statistical analysis was performed
by a Student’s t-test. Diﬀerences were considered signiﬁcant
when P<. 05.
3. Results andDiscussion
3.1. Protective Immunity Generated by s.c. Vaccination with
L R P+C p GO D Ni nt h eF o o t p a d .In a previous work we
showed that BALB/c mice vaccinated with LRP combined
with CpG ODN were protected against the development of
cutaneous lesions in the footpad 8 weeks after parasite chal-
lenge [15]. The absence of footpad swelling was correlated
with a 3-log reduction in parasite burden in the ipsilateral
popliteal DLN when compared with mice immunized with
the adjuvant or the excipient (control groups) [15]. In
addition, no parasites were found in the spleen of the LRP
+ CpG ODN vaccinated animals whereas control groups
contained approximately 104 parasites. It was concluded that
the Th1 immune response induced in BALB/c mice by the
vaccination of the LRP combined with CpG ODN resulted in
a solid immunity that eﬃciently controlled parasite induced
cutaneous disease maintaining a chronic infection in the
local DLN [15]. In this work, we decided to analyze the
footpad swelling of LRP + CpG ODN vaccinated mice after
a longer period of time. After parasite challenge, vaccinated
mice did not develop lesion for up to eighteen weeks
(Figure 1(a)). Since control groups were sacriﬁced at week
seven after challenge (because they began to develop severe
necrotic lesions) a comparative analysis between controls
and LRP + CpG ODN vaccinated mice was not possible.
However, the parasite burden in the spleen and in the
popliteal DLN of the LRP + CpG ODN vaccinated mice was
analyzedatweek18afterparasitechallengeinthefootpad.As
it is shown in Figure 1(b), no parasites could be detected in
the spleen of the vaccinated mice. The number of parasites
located at the popliteal DLN at week 18 after challenge
(5.41 ± 0.99; log10 scale) represents a 1.12-log increment
(P = .23) when compared with the number of parasites
detected in the same organ in LRP + CpG ODN vaccinated
mice 8 weeks after challenge (4.84 ± 0.26; log10 scale) [15].
Although a slightly increment in the number of parasites was
detected, the presence of high levels of IFN-γ measured in
the supernatants of DLN cells cultures after stimulation with
SLA and LRP in the absence of detectable levels of IL-4 and
IL-10 (Figure 1(c)), should be taken as an indication that
the parasite-speciﬁc Th1 response observed at week 8 [15]
was maintained at week 18 after challenge. Thus, the Th1
response elicited by LRP + CpG ODN vaccination was able
to induce an immunological status that protects mice against
the development of cutaneous lesions during the 18 weeks of
follow up. In addition, a chronic infection was patent in the
vaccinated mice, being the parasites maintained located in
the local DLN without dissemination to the internal organs.
This study reinforces that CpG ODN provides protection
when used in combination with LRP extracts. Previous
studies using this adjuvant in combination with parasite
lysates showed a diﬀerent degree of protection against L.
major infection in the susceptible BALB/c [19–21] and in
the resistant C57BL/6 [19] mice strains. The identiﬁcation
of a protein fraction composed by ribosomal proteins that
provide protection against the development of cutaneous
leishmaniasis lesions represents a substantial step in deﬁning
the protective immunogens within SLA, helping to identify
new protective parasite antigens for the development of
molecularly deﬁned vaccines against leishmaniasis.
3.2. Protected Mice Became Resistant to Disease Caused by a
L. major Rechallenge in the Ear Dermis. Next, we analyzed
if protected mice were able to control a second parasite
challenge. For that purpose, vaccinated and protected mice
(n = 6) were rechallenged in the ear dermis with 1000
L. major metacyclic promastigotes, parasite infective forms
that seem to be similar to the promastigotes that are
inoculated during the insect vector blood feeding [22]. Since
vaccines were inoculated in the contralateral footpad of
the primary infection site, rechallenge was made by i.d.
infection in the ears. BALB/c mice infected with a low dose
of L. major metacyclic promastigotes develop progressive
inﬂammatory lesion in the spot of infection that increased in
size, accompanied by ulceration and tissue necrosis [23–26]
as occurred in mice challenged in the footpad with a high
dose inoculum of stationary promastigotes [3, 4]. As control
six na¨ ıve BALB/c mice were also infected in the ear dermis
with the same dose of parasites.
Very low dermal lesion development was observed in
reinfected mice (Figure 2(a)). In some cases (in four of
six mice) a complete absence of inﬂammation in the ears
was observed for up to seven weeks. Two mice developed
low dermal lesions (<1mm) that reached a peak at week
5 and were almost completely healed at week seven. On4 Journal of Biomedicine and Biotechnology
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Figure 1: Course of L. major infection in BALB/c vaccinated mice. Mice (six per group) were s.c. immunized in the right footpad with
three doses of the LRP adjuvated with CpG ODN (LRP + CpG), with the CpG ODN adjuvant (CpG) or with PBS. One month after the last
immunization, the animals were infected in the left hind footpad with 5×104L. major stationary phase promastigotes. (a) Footpad swelling
is given as the diﬀerence of thickness between the infected and the uninfected contralateral footpad. (b) The number of viable parasites in
the spleen and the popliteal DLN of the LRP + CpG ODN vaccinated were individually determined by limiting dilution at week eighteen
post challenge. Results are expressed as the mean±SD of six spleens and popliteal DLN. (c) At week eighteen after footpad infection the level
of IFN-γ, IL-10 and IL-4 was measure by ELISA in the supernatants of popliteal lymph node cells cultures from LRP + CpG ODN vaccinated
mice. Cells were in vitro stimulated for 48 hours with 12μg/ml of SLA or LRP and medium alone. Results are expressed as the mean±SD.
the other hand, infection in all control na¨ ıve mice leads
to the development of progressive inﬂammatory lesions
in the ears (Figure 2(a)). The parasite load in the ear
dermis and retromaxillar DLN was analyzed at week seven
after challenge. Vaccinated and reinfected mice showed very
low parasite loads in the ears and in the retromaxillar
DLN, correlating to the absence of parasite in the spleens
(Figure 2(b)). These data contrast with the parasite burdens
found in the ear dermis and in the retromaxillar DLN in
the control group mice. Also, as an indication of parasite
dissemination, parasites were detected in the spleen of the
control mice (Figure 2(b)). These data indicate that the
immune state generated after the ﬁrst infection in the LRP
+ CpG ODN vaccinated mice is extremely potent, leadingJournal of Biomedicine and Biotechnology 5
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Figure 2: (a) Course of L. major infection in protected and reinfected BALB/c mice. Values represent the mean lesion diameter±standard
deviation (SD). ∗P<. 001: signiﬁcant diﬀerences in inﬂammation for protected versus control mice at week seven postchallenge. (b) Seven
weeks after reinfection, mice were euthanized and parasite burden in the ear dermis, spleen and in the retromaxillar DLN was individually
quantitated. Results are expressed as the mean±SD of twelve ears and six spleens and DLN. ∗P<. 001: signiﬁcant decrease for reinfected
versus control mice. (c) The parasite burden at week seven after rechallenge was individually quantitated in the popliteal lymph nodes of
control and reinfected mice. Results are expressed as the mean±SD of six DLN. ∗P<. 001: signiﬁcant decrease for reinfected versus control
mice.
to a rapid and eﬃcient control of parasite growth in the site
of reinfection, that resulted in the generation of a moderate
dermal pathology.
In the vaccinated reinfected mice the primary challenge
site was also analyzed, since in immune genetically resistant
mice an L. major secondary challenge can cause disease
reactivation in the primary site despite eﬃcient parasite
clearance in the site of reinfection [27, 28]. The parasite load
found in the popliteal DLN of the reinfected mice (6.68 ±
0.63; log10 scale) (Figure 2(c)) represents an increment of
1.23-log (P = .028) when compared with the number of
parasites detected at the moment of the secondary challenge.
SincenoparasiteswerefoundinthepoplitealDLNofcontrol
mice (Figure 2(c)), parasite dissemination from the ear to6 Journal of Biomedicine and Biotechnology
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Figure 3: Analysis of the cellular responses. At week seven after ear infection the level of IFN-γ (a), IL-10 (b), and IL-4 (c) was measured by
ELISA in the supernatants of spleen and retromaxillar lymph node cells cultures from both mice groups. Cells were in vitro stimulated for
48 hours with 12μg/ml of SLA or LRP and medium alone. Results are expressed as the mean±SD of twelve ears and DLN. (∗P<. 001).
these lymph nodes seems to be unlikely and the increase in
the number of parasites found in the popliteal DLN may
be indicating that the secondary challenge induced some
parasitereplication.However,wedidnotdetectanincrement
in the footpad swelling in the vaccinated reinfected BALB/c
mice for up to seven weeks after secondary challenge (not
shown). Thus, we conclude that secondary challenge in the
ear dermis did not produce a disease reactivation in these
vaccinated mice.
3.3. Analysis of the Cellular Immune Response. To determine
which immunological parameters are related to resistance
after the secondary challenge, the SLA and the LRP driven
production of IL-4, IL-10, and IFN-γ was assayed at week
seven after ear infection. Spleen cell cultures from control
and reinfected mice were established to analyze the systemic
response and DLN cells (retromaxillar) were cultured to
analyze the local response induced by the ear infection.
Spleen cells from reinfected mice produced higher amounts
of IFN-γ after SLA or LRP stimulation than control mice,
but only the level of LRP speciﬁc IFN-γ was signiﬁcantly
diﬀerent between the two groups. We observed that the level
of SLA- and LRP-speciﬁc IFN-γ detected in the DLN cell
cultures was higher in control than in the reinfected mice
(Figure 3(a)). Most likely, the high level of IFN-γ detected
in retromaxillar DLN could be related to the high number
of parasites found in control animals (Figure 2(b)) that may
be stimulating the production of IFN-γ by Th1 cells, since in
this model of infection the presence of parasites is correlated
with IFN-γ production [26]. The IL-10 and IL-4 production
after stimulation with SLA or LRP was barely detected in the
spleen and DLN cells from reinfected mice whereas in the
spleen cell cultures and especially in the DLN cell culture
supernatantsfromcontrolmicehighlevelsofthesecytokines
were measured (Figures 3(b) and 3(c)).
Those data are compatible with the fact that Th1/Th2
mixed responses were elicited after infection in control mice,
characterized by the production of parasite speciﬁc IFN-
γ and IL-4 cytokines. In addition, the presence of high
levels of parasite speciﬁc IL-10 may be also implicated in
the progression of the disease, since the inactivating eﬀect
of this cytokine in infected macrophages has been relatedJournal of Biomedicine and Biotechnology 7
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Figure 4: Analysis of the humoral responses. Serum samples from control and vaccinated reinfected mice were obtained seven weeks after
challenge in the ear dermis. The titre for IgG1 and IgG2a antibodies against LRP (a) and SLA (b) was determined individually by ELISA.
Results are expressed as the mean±SD.
Table 1: Cytokine production by popliteal DLN cells from vaccinated reinfected mice at week seven after secondary challenge.
SLA LRP Medium
IFN-γ 5837.16 ±834.82 5773.52 ±1411,14 1635,11 ±607,89
IL-10 526.31 ±214.98 408,92 ±233.36 104,39 ±57,13
IL-4 229.54 ±58.78 44.36 ±31.22 54.38 ±37.89
The level of cytokines was determined by ELISA in the supernatant of popliteal DLN cells obtained from reinfected mice at week seven post rechallenge, after
in vitro stimulation with 12μg/ml of SLA and LRP. Mean±SD of samples from six mice is shown (pg/ml).
with BALB/c mice susceptibility against L. major infection
[29–32]. The pattern of cytokine production observed in
infected control mice, with detectable level of parasite
speciﬁc production of IFN-γ, IL-10 and IL-4 was previously
observed after infection with a pathogenic challenge of L.
major in BALB/c ears [25, 26, 33]. On the contrary, a Th1-
mediated IFN-γ production was elicited in the reinfected
mice group in the absence of Th2 responses and IL-10
mediated regulatory responses.
T h eS L Aa n dt h eL R Pd r i v e np r o d u c t i o no fI L - 4 ,I L -
10, and IFN-γ was also assayed in the popliteal DLN of
the reinfected mice. Although detectable levels of the three
cytokines were observed, the level of IFN-γ was higher
than the levels of IL-10 and IL-4 (Table 1). A high ratio
of IFN-γ/IL-10 and IFN-γ/IL-4 for both parasite proteins
preparations(11.1and25.5forSLA;14.1and130.15forLRP,
respectively) was obtained, indicating that a parasite-speciﬁc
IFN-γ response was still maintained at week seven after
secondary challenge in the popliteal DLN, yet in the presence
of IL-4 and IL-10 cytokines. This Th1/Th2 mixed response
may account for the increment observed in the number of
parasites after secondary infection in the popliteal DLN.
3.4. Analysis of the Humoral Responses. The humoral re-
sponse elicited in control mice and in the reinfected mice
was analyzed at week seven after parasite challenge in the
ear dermis. The titre of anti-LRP and anti-SLA speciﬁc IgG1
and IgG2a antibodies were determined, since the presence of
IgG1 and IgG2a antibodies is considered a marker of Th2
and Th1 type responses, respectively [34]. In the sera from
control mice the anti-Leishmania predominant antibodies
were of the IgG1 isotype and very low but detectable
levels of IgG2a were observed (Figures 4(a) and 4(b)). On
the contrary, vaccinated reinfected mice showed high titres
of IgG2a antibodies against LRP (Figure 4(a))a n dS L A
(Figure 4(b)). These humoral responses are in agreement
with the nature of cellular responses observed after in vitro
stimulation with both antigenic preparations. A strong Th1
response was elicited in vaccinated reinfected mice after
parasite rechallenge having a resistant phenotype. On the
contrary, antibodies found in the sera from mice of the
control group were mainly of the IgG1 isotype as expected
for their nonhealing phenotypes.
Altogether, our data showed that the immune response
elicited in the LRP + CpG ODN vaccinated mice after8 Journal of Biomedicine and Biotechnology
the primary infection was able to control a secondary chal-
lenge. Acquisition of the resistant phenotype was correlated
to the capacity to induce a Th1 response (large amounts
of parasite speciﬁc production of IFN-γ and a high anti-
leishmanial proteins IgG2a/IgG1 ratio) in the absence of
Th2 or IL-10 mediated responses. The immune responses
associated with the resistance after secondary infection in
the vaccinated-infected mice were similar to that obtained
in BALB/c mice that controlled a secondary infection in the
ear after a primary infection in the contralateral ear, showing
a Th1 response after rechallenge [26]. It is important to
note that protection in these mice only occurred when
lesions were developed in the primary site of infection [26],
whereas LRP + CpG ODN vaccinated mice became resistant
after primary challenge without the development of dermal
lesions. Also, protection to reinfection achieved by BALB/c
mice infected with a low infection dose in the footpad
was dependent on the induction of Th1 responses [11, 35].
Here we show that that the immune response elicited by
the LRP + CpG ODN vaccine after primary challenge was
able to control the development of lesions and generated a
long-term immune state necessary for the maintenance of
immunity to further infection. The presence of parasites in
the popliteal DLN may be related with this Th1 response,
since it has been demonstrated that the presence of parasite
antigens is necessary for the maintenance of cell mediated
immunity in BALB/c mice [14, 36].
4. Conclusion
The data reported here provided evidence that BALB/c mice
protected against the development of dermal pathology due
to L. major s.c challenge after LRP + CpG ODN vaccination
have acquired an immunological status which conferred
them the capacity to resist a further infection (an appealing
feature for a vaccine that might be employed in endemic
areas, where reexposure to the parasite would be very fre-
quent). After a secondary challenge in the ear dermis, these
mice showed a robust protection against L. major infection.
Very low parasite burdens and development of dermal
lesions in the site of reinfection were found. A speciﬁc
Th1 protective response after the secondary challenge was
correlated to resistance to reinfection. Thus, the immune
state generated by the combination of vaccination with LRP
+ CpG ODN and the primary infection is extremely potent,
leading to a rapid and eﬃcient elimination of the parasite
from the site of reinfection. Despite extensive research
eﬀorts, leishmanization with viable Leishmania parasites is
the only vaccine with proven eﬃcacy in humans [2, 37].
The induction of long-term immune responses by vaccines
based on parasite extracts or recombinant parasite products
thatprotectedmiceagainstthedevelopmentofleishmaniosis
after a primary challenge has been extensively reported [8,
38]. However, there is scarcity of studies analyzing the long-
term maintenance of resistance to reinfection of vaccinated
mice. Extrapolation of this approach to other animal or
humanmodelsishazardousbutourﬁndingsmayberelevant
to develop eﬀective tools against leishmaniasis based on
deﬁned Leishmania subunits.
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